

ZETA Strengthens Partnership with Swiss CB Consultancy: Combining technical forces for optimized services.

ZETA is thrilled to announce that it has recently signed contracts for the acquisition of shares in the Swiss company CB Consultancy. As part of this agreement, ZETA acquired a 20% share in CB Consultancy, the deal has been closed by July 14, 2023.

The path of newly developed compounds from the laboratory to preclinical phase and early clinical GxP production, followed by scaling up the manufacturing process to industrial scale, to market launch in secure routine production facility is a complex challenging process for the pharmaceutical and biotech industry. Risk and complexity management in manufacturing biopharmaceutical products are central challenges confronting companies in this industry.

As an engineering specialist for biopharmaceutical process plants, ZETA relies on the cooperation with the experienced engineering specialist CB Consultancy, which successfully proves its know-how especially in the initiation of projects. An innovative joint approach from which all companies in the industry can benefit.

Joint engineering know-how for the pharmaceutical and biotech industries

CB Consultancy is renowned for its professional services in planning, construction management, and operation of industrial facilities in various sectors, including pharmaceuticals, biotechnology, chemicals, analytical and scientific service providers, and the med-tech industry. Their esteemed clientele includes Takeda, Novartis, Johnson & Johnson, and Sinopharm.

“The cooperation between CB Consultancy and ZETA has proven its worth since 2013,” explains Andreas Marchler, CEO of ZETA Holding, and continues, “Building on this strong foundation of trust and successful collaboration, CB Consultancy and ZETA have decided to further deepen their cooperation through this share acquisition.”

Mastering the challenges of the future together

Through this partnership, both companies aim to leverage their respective skills and expertise in project execution. By combining their strengths, ZETA and CB Consultancy work closely together in project initiation and execution, focusing on conceptual optimization within the project lifecycle.

ZETA and CB Consultancy look forward to continuing their successful partnership, as they jointly strive to provide exceptional services and innovative solutions to their clients in the industry.

About

The ZETA Group, with 1.300 highly qualified employees and 28 subsidiaries worldwide, specializes in planning, automation, digitalization and maintenance of customized biopharmaceutical facilities for aseptic process solutions. ZETA acts as a one-stop-shop, combining plant engineering with HVAC and cleanroom design.

As a general planner, ZETA manages the high complexity of large-scale pharmaceutical projects and specifically reduces interfaces - from the planning and construction of the process plant to the cleanroom design and technical building equipment. This design-build approach accelerates project execution time by up to 50% and leads to earlier value creation in the customer's capex projects. As a result, ZETA actively contributes to faster time-to-market of vital compounds and patients benefit from earlier availability of drugs such as anticancer agents, insulin and vaccines.

ZETA is actively taking steps towards a more sustainable future for the industry as a whole. Through ZETA's decarbonization strategies, emissions are specifically reduced during the biopharmaceutical manufacturing process.

Contact

Andreas Marchler

Managing Director ZETA Group
+43 (3136) 9010 1002
andreas.marchler@zeta.com

Christian Bachofen

Managing Director CB Consultancy AG
+41 79 215 24 14
christian.bachofen@cbconsultancy.ch

Photographic material

Reprint with ZETA copyright notice free of charge



Andreas Marchler emphasizes that collaboration with ZETA will lead to a faster market launch of biopharmaceutical active ingredients.



Christian Bachofen relies on professional engineering for large-scale projects, starting in the early phase of project initiation.